Skip to main content
Equibles

EOCN · Galmed Pharmaceuticals Ltd. · Documents

Track EOCN — free

Use EOCN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EOCN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.39 -0.09 (-3.63%) At close · Nov 12 Q4 2021 earnings call transcript
Rebalance outlook locked
Market Cap
$2.55M
Shares
1.07M
Volume · Nov 12 3434 Avg daily vol (53 sessions) 18.38K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $10.31M 20-F filed Mar 31, 2026 Earnings call Q4 2021 earnings call Held Dec 31, 2021
2026
Nov 10
Current report 6-K
CG-100 secured exclusive European distribution rights

Eocene Ltd.’s Colospan Ltd. entered its first European distribution agreement with Hospital Line SA, granting exclusive rights to market, sell and distribute CG-100 in Greece and Cyprus. A planned launch is expected to run alongside Colospan’s ongoing U.S. pivotal study.

3 source passages
Eocene Ltd. (NASDAQ: EOCN) (“Eocene” or the “Company”) today announced that its wholly owned subsidiary, Colospan Ltd. (“Colospan”), has entered into its first European commercial distribution agreement for its CG-100 device with Hospital Line SA (“Hospital Line”). Under the agreement, Hospital Line has been granted exclusive rights to market, sell and distribute CG-100 in Greece and Cyprus. The planned commercial launch of CG-100 in Greece and Cyprus is expected to proceed in parallel with Colospan’s ongoing U.S. pivotal study of CG-100. Open the document at this passage
Mar 31
Annual report 20-F FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss $10.31M Diluted EPS $2.39 ▼ 70.4%
2025
Showing 1–50 of 161 documents
Key facts CIK 1595353 CUSIP M47238205 13F (30d) 5 filings 5 filers Visit website Investor relations